This is a promising development on the way to a less painful treatment. 🧐
During the experimentation process, the patients were given dostarlimab every three weeks for six months, and chemoradiotherapy and surgery were set to follow in case of tumors returned. But in the end, there was no trace left from the tumors to be seen through MRI scans, PET scans, endoscopy, and biopsy.
So far, almost three-quarters of patients have suffered mild or moderate side effects, such as rash, itching, tiredness, and nausea. Besides that, none of them has experienced regrowth in cancer, with the median follow-up being one year and some patients remaining cancer-free for two years.only 12 patients
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Experimental rectal cancer drug caused all patients' tumors to disappear in small trialSo far, no patient has needed further treatment.
Read more »
Small Rectal Cancer Study Has Remission in Every PatientA small clinical trial with 12 rectal cancer patients found remission in 100% of them, according to a new paper published in The New England Journal of Medicine.
Read more »
Every cancer patient enters remission after drug trial, study revealsA recent drug trial administered at Memorial Sloan Kettering Cancer Center to a handful of cancer patients wiped out the disease in every participant.
Read more »
Every Single Patient in This Small Experimental Drug Trial Saw Their Cancer DisappearIn what appears to be a very promising breakthrough for the treatment of rectal cancer, a small drug trial conducted in the US found every patient treated in the experiment had their cancer successfully go into remission.
Read more »
NPR Cookie Consent and Choices
Read more »
'Tumors just vanished': Cancer patients now in remission after drug trial - CNN VideoAn immunotherapy showed promising results in a small trial of rectal cancer patients, according to new research, but further study is needed and it is too early to call it a cure. ErinBurnett talks to oncologist Dr. Andrea Cercek about the trial:
Read more »